Special Issue "Recent Advances in Gynecologic Oncology"

A special issue of Reproductive Medicine (ISSN 2673-3897).

Deadline for manuscript submissions: 31 August 2022 | Viewed by 987

Special Issue Editors

Prof. Dr. Iztok Takač
E-Mail Website
Guest Editor
Divison of Gynecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia
Interests: gynecologic oncology; ultrasound; breast cancer
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Jure Knez
E-Mail Website
Guest Editor
Department of Gynaecology and Obstetrics, Faculty of Medicine University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia
Interests: endometrial cancer; endometriosis; biomarkers in gynecology; ultrasound; gynecological oncology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Darja Arko
E-Mail Website
Guest Editor
Divison of Gynecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia
Interests: breast cancer; gynecologic oncology; ultrasound
Prof. Dr. Andraž Dovnik
E-Mail Website
Guest Editor
Divison of Gynecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia
Interests: gynecologic oncology; colposcopy; preventive medicine

Special Issue Information

Dear Colleagues,

Gynecologic oncology is a rapidly evolving field of medicine that integrates knowledge from various fields and often requires a multidisciplinary approach when planning the treatment. Clinical, radiological and molecular information must all be included in the treatment plan. Recent molecular advances in endometrial and ovarian cancer have improved our understanding of these diseases and their response to treatment and moved the trend of treatment towards personalized medicine. There are, however, still many questions that remain unanswered, such as the best approach in advanced ovarian cancer, the role of neoadjuvant chemotherapy in fertility-sparing treatment of cervical cancer, and many more. This Special Issue aims to answer these seemingly unanswerable questions.

Prof. Dr. Iztok Takač
Prof. Dr. Jure Knez
Prof. Dr. Darja Arko
Prof. Dr. Andraž Dovnik
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reproductive Medicine is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • ovarian cancer
  • cervical cancer
  • vulvar cancer
  • ultrasound
  • colposcopy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Ovarian Cancer: Treatment and Resistance to Pharmacotherapy
Reprod. Med. 2022, 3(2), 127-140; https://doi.org/10.3390/reprodmed3020011 - 09 May 2022
Viewed by 532
Abstract
Despite advances in surgical techniques and chemotherapy, ovarian cancer is still a leading cause of death among gynecological cancers. In addition to the late detection of the disease, the main reason for poor prognosis is resistance to pharmacotherapy, mostly platinum compounds. About a [...] Read more.
Despite advances in surgical techniques and chemotherapy, ovarian cancer is still a leading cause of death among gynecological cancers. In addition to the late detection of the disease, the main reason for poor prognosis is resistance to pharmacotherapy, mostly platinum compounds. About a third of patients do not respond to primary platinum-based chemotherapy treatment, and over time, eventually, 80% of other patients develop chemoresistance, which makes the recurrence of disease incurable. In this review, we describe a difficult clinical hurdle faced in ovarian cancer therapy as a result of platinum resistance, as well as resistance to newer targeted therapy with PARP inhibitors and bevacizumab. We, furthermore, give attention also to the role of the tumor microenvironment as it is less well understood than the tumor cell-intrinsic mechanism. Because a central goal in ovarian cancer research is the development of novel strategies to overcome chemoresistance, treatment for cancer is moving toward personalized therapy. Full article
(This article belongs to the Special Issue Recent Advances in Gynecologic Oncology)
Show Figures

Figure 1

Back to TopTop